Sameek Roychowdhury, MD, PhD, James Cancer Hospital & Solove Research Institute

Articles

Perspectives on Treating CCA Moving Forward

May 3rd 2021

A panel of GI oncologists share their thoughts on the future of using precision medicine to treat patients with bile duct cancers.

Immunotherapy for Advanced Cholangiocarcinoma

May 3rd 2021

The role of MSI testing and potential use of immunotherapy to treat patients with advanced cholangiocarcinoma.

Cholangiocarcinoma: Potential Therapies Under Investigation

April 26th 2021

An overview of various treatment opportunities under study that are looking at using novel techniques to help personalize treatment for patients with bile duct cancers.

IDH Targeting in Advanced Cholangiocarcinoma

April 26th 2021

Considerations for treating appropriate patients with advanced cholangiocarcinoma with an IDH inhibitor.

Implications for Using FGFR Inhibitors in Advanced CCA

April 19th 2021

Milind Javle, MD, of The University of Texas MD Anderson Cancer Center, explains what GI oncologists can expect from FGFR treatment for advanced cholangiocarcinoma in terms of treatment responses.

FGFR Inhibitors for Advanced Cholangiocarcinoma: Adverse Events

April 19th 2021

Recommendations for appropriately managing patients who experience adverse events associated with FGFR treatment for advanced cholangiocarcinoma.

FGFR Inhibitors for Advanced Cholangiocarcinoma

April 12th 2021

R. Kate Kelley, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, comments on the rationale for treating patients with advanced cholangiocarcinoma with an FGFR inhibitor.

Promoting the Importance of Molecular Testing in CCA

April 12th 2021

The value of early molecular testing in cholangiocarcinoma and importance of promoting its role to both patients and GI oncologists.

Advanced Cholangiocarcinoma: Molecular Testing 

April 5th 2021

Experts who treat patients with GI cancers, such as cholangiocarcinoma, emphasize the need for more standardized approaches to molecular testing. 

Advanced Cholangiocarcinoma: Transition to Precision Medicine 

April 5th 2021

A panel of GI oncologists comment on the transition to targeted therapy and immunotherapy as treatments for advanced cholangiocarcinoma, as well as highlight predictive and prognostic markers that can help guide treatment decisions with novel therapies.